Drug Overview

Axitinib is a highly potent, selective tyrosine kinase inhibitor (TKI) designed to disrupt the blood supply to tumors. It is a cornerstone therapy in the management of kidney cancer, particularly noted for its flexibility in dosing and its pivotal role in modern combination immunotherapy regimens.

Generic Name: Axitinib
US Brand Names: Inlyta®
Drug Class: Tyrosine Kinase Inhibitor (VEGFR Inhibitor)
Route of Administration: Oral (Tablets)
FDA Approval Status: Approved for the treatment of advanced renal cell carcinoma (RCC) as a single agent and in combination with immunotherapy.

What Is It and How Does It Work? (Mechanism of Action)

Axitinib works as a potent inhibitor of angiogenesis, the process by which tumors grow new blood vessels to feed themselves.

Molecular Target: The drug selectively inhibits Vascular Endothelial Growth Factor Receptors (VEGFR-1, VEGFR-2, and VEGFR-3). It binds to the intracellular tyrosine kinase domains of these receptors.
Blockade of Signaling: By blocking these receptors, Axitinib prevents the phosphorylation required for downstream signaling. This effectively shuts down the proliferation and migration of endothelial cells (cells that line blood vessels).
Tumor Starvation: Without a functional blood supply, the tumor is deprived of oxygen and nutrients, leading to growth arrest and tumor shrinkage. Axitinib is significantly more potent (up to 450 times) against VEGFRs than first-generation inhibitors like sunitinib.

FDA-Approved Clinical Indications

Axitinib is currently FDA-approved exclusively for kidney cancer, where it is used in multiple settings.

Oncological Uses:

Advanced Renal Cell Carcinoma (First-Line Combination): Indicated in combination with pembrolizumab (Keytruda®) or avelumab (Bavencio®) for the first-line treatment of patients with advanced renal cell carcinoma.
Advanced Renal Cell Carcinoma (Second-Line Monotherapy): Indicated as a single agent for the treatment of advanced renal cell carcinoma after the failure of one prior systemic therapy (e.g., sunitinib or cytokine therapy).

Non-Oncological Uses:

There are no FDA-approved non-oncological indications.

Dosage and Administration Protocols

Axitinib has a unique dosing feature: it allows for “up-titration” (increasing the dose) in patients who tolerate the drug well, to maximize efficacy.

Standard Oncology Dosage:

Starting Dose: 5 mg twice daily.
Frequency: Approximately 12 hours apart.
Administration: Swallow whole with a glass of water. Can be taken with or without food.

Dose Titration Protocol:

If the patient tolerates the starting dose for 2 consecutive weeks with no adverse events > Grade 2 and blood pressure is < 150/90 mmHg, the dose can be increased.

Step	Dose	Frequency
Starting Dose	5 mg	Twice Daily
First Increase	7 mg	Twice Daily (if 5 mg is tolerated)
Second Increase	10 mg	Twice Daily (if 7 mg is tolerated)

Organ Function Adjustments:

Condition	Recommended Dose	Protocol Note
Mild/Moderate Renal Impairment	5 mg BID	No adjustment required
Severe Renal Impairment	Use Caution	Not studied extensively
Mild Hepatic Impairment	5 mg BID	No adjustment (Child-Pugh A)
Moderate Hepatic Impairment	2 mg BID	Reduce starting dose (Child-Pugh B)
Severe Hepatic Impairment	Not Recommended	Avoid use (Child-Pugh C)

Clinical Efficacy and Research Results

Recent data (2020-2025) confirm Axitinib’s status as a standard-of-care “backbone” partner for immune checkpoint inhibitors.

Axitinib + Pembrolizumab (KEYNOTE-426): Long-term follow-up confirms superior Overall Survival (OS) and Progression-Free Survival (PFS) compared to sunitinib. The median PFS is approximately 15.4 months for the combination vs. 11.1 months for sunitinib. The Objective Response Rate (ORR) is consistently near 60%.
Axitinib + Avelumab (JAVELIN Renal 101): This combination demonstrated a significant PFS benefit (median 13.8 months) compared to sunitinib in PD-L1-positive tumors. It remains a preferred option for low-risk disease groups.
Real-World Evidence (2022-2024): Real-world studies involving over 350 patients mirrored clinical trial results, showing a 12-month survival rate of nearly 90% for first-line combination users, validating its efficacy outside of controlled trials.

Safety Profile and Side Effects

Important Safety Warnings:

Axitinib does not have a Black Box Warning, but it carries severe warnings regarding Hypertension, Cardiac Failure, and Thrombotic Events.

Common Side Effects (>10%)

Hypertension: High blood pressure is the most common side effect (approx. 40-50%) and is often a marker of drug efficacy. It must be managed aggressively.
Gastrointestinal: Diarrhea (very common), nausea, vomiting, and constipation.
General: Fatigue, dysphonia (hoarseness of voice), and decreased appetite.
Dermatologic: Palmar-plantar erythrodysesthesia (Hand-Foot Syndrome) – redness/peeling of hands and feet.

Serious Adverse Events

Arterial/Venous Thrombotic Events: Increased risk of heart attack, stroke, or pulmonary embolism.
Gastrointestinal Perforation: Rare but fatal hole formation in the stomach or intestine. Patients with a history of diverticulitis are at higher risk.
Reversible Posterior Leukoencephalopathy Syndrome (RPLS): A neurological emergency causing headache, seizure, lethargy, and blindness. Requires immediate discontinuation.
Wound Healing Complications: As an angiogenesis inhibitor, it prevents wounds from healing.

Management Strategies:

Hypertension: Patients often require the addition of antihypertensive medications (e.g., amlodipine) rather than stopping the cancer drug.
Diarrhea: Managed with loperamide and hydration; severe cases require dose reduction.

Connection to Stem Cell and Regenerative Medicine

Axitinib is at the intersection of vascular biology and tumor immunology, influencing the tumor microenvironment in ways that affect stem cell therapies.

Vessel Normalization: Aberrant tumor blood vessels prevent immune cells and drugs from reaching the tumor core. Axitinib “normalizes” this vasculature, potentially improving the delivery of CAR-T cells or other cellular therapies in combinatorial trials.
Targeting Cancer Stem Cells (CSCs): Hypoxia (low oxygen) created by anti-angiogenic drugs can sometimes drive cancer cells into a dormant, “stem-like” state. Research suggests that combining Axitinib with metabolic inhibitors or immunotherapy can target these resistant CSC populations, preventing relapse.
Reversing Immunosuppression: Preclinical models show Axitinib reduces the number of myeloid-derived suppressor cells (MDSCs) in the tumor. Since MDSCs suppress the immune system, their removal “wakes up” the body’s T-cells, creating a synergistic effect with immune checkpoint inhibitors.

Patient Management & Practical Recommendations

Pre-Treatment Tests:

Blood Pressure: Must be well-controlled (<140/90) before starting.
Thyroid Function: Baseline TSH, as hypothyroidism is common.
Liver Function Tests: ALT/AST and Bilirubin to determine dosing.
Urinalysis: To check for proteinuria (protein in urine).

Precautions During Treatment:

Surgery: Stop Axitinib at least 24 hours before any planned surgery (including dental surgery) to avoid wound healing complications.
Bleeding: Patients should monitor for black stools or coughing up blood.

Do’s and Don’ts:

DO: Monitor blood pressure at home daily or weekly as advised. Report readings >150/90 mmHg.
DO: Keep hands and feet moisturized with urea-based creams to prevent skin peeling.
DON’T: Eat grapefruit or drink grapefruit juice; it blocks the enzyme (CYP3A4) that clears the drug, leading to toxic overdose.
DON’T: Ignore a sudden severe headache or vision change; go to the ER immediately (RPLS risk).

Disclaimer

This guide is for informational purposes only and is intended for international patients and healthcare professionals. It does not replace professional medical advice, diagnosis, or treatment. Dosing and protocols may vary by patient status and local regulatory guidelines. Always consult with a qualified oncologist or healthcare provider regarding specific medical conditions.